Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Preclinical Evaluation of UAB30 in Pediatric Renal and Hepatic Malignancies

Alicia M. Waters, Jerry E. Stewart, Venkatram R. Atigadda, Elizabeth Mroczek-Musulman, Donald D. Muccio, Clinton J. Grubbs, Elizabeth A. Beierle

Mol Cancer Ther (2016) 15 (5): 911–921.

https://doi.org/10.1158/1535-7163.MCT-15-0521

Published: 05 May 2016

View article titled, Preclinical Evaluation of UAB30 in Pediatric Renal and Hepatic Malignancies

Includes: Supplementary data

Journal Articles

Preclinical Evaluation of a Novel RXR Agonist for the Treatment of Neuroblastoma

Alicia M. Waters, Jerry E. Stewart, Venkatram R. Atigadda, Elizabeth Mroczek-Musulman, Donald D. Muccio, Clinton J. Grubbs, Elizabeth A. Beierle

Mol Cancer Ther (2015) 14 (7): 1559–1569.

https://doi.org/10.1158/1535-7163.MCT-14-1103

Published: 06 July 2015

View article titled, Preclinical Evaluation of a Novel RXR Agonist for the Treatment of Neuroblastoma

Includes: Supplementary data

Journal Articles

Abstract A82: Bardoxolone (5MeCDDO), which induces the antioxidant response element (ARE), is ineffective in inhibiting cancer progression but inhibits cancer initiation in rodent models of cancer. What does it mean for the ARE as a primary prevention target?

Ronald A. Lubet, Reid Townsend, Margie L. Clapper, Vernon E. Steele, Clinton J. Grubbs

Mol Cancer Ther (2011) 10 (11_Supplement): A82.

https://doi.org/10.1158/1535-7163.TARG-11-A82

Published: 12 November 2011

View article titled, Abstract A82: Bardoxolone (5MeCDDO), which induces the antioxidant response element (ARE), is ineffective in inhibiting cancer progression but inhibits cancer initiation in rodent models of cancer. What does it mean for the ARE as a primary prevention target?

Journal Articles

Abstract A84: Lack of efficacy of the anti-diabetic drug metformin in the ER+ methylnitrosourea (MNU)-induced and the ER⁻ MMTV-Neu/p53KO models of mammary cancer.

Clinton J. Grubbs, Margie Clapper, Ann Bode, Vernon Steele, Ronald Lubet

Mol Cancer Ther (2011) 10 (11_Supplement): A84.

https://doi.org/10.1158/1535-7163.TARG-11-A84

Published: 12 November 2011

View article titled, Abstract A84: Lack of efficacy of the anti-diabetic drug metformin in the ER+ methylnitrosourea (MNU)-induced and the ER<sup>−</sup> MMTV-Neu/p53KO models of mammary cancer.

Journal Articles

Abstract A80: Modified dosing schedules with the EGFr inhibitors gefitinib and lapatinib in rodent models of mammary and urinary bladder cancer: Preventive and therapeutic effects.

Ronald Lubet, Ann Bode, Eva Szabo, Clinton J. Grubbs

Mol Cancer Ther (2011) 10 (11_Supplement): A80.

https://doi.org/10.1158/1535-7163.TARG-11-A80

Published: 12 November 2011

View article titled, Abstract A80: Modified dosing schedules with the EGFr inhibitors gefitinib and lapatinib in rodent models of mammary and urinary bladder cancer: Preventive and therapeutic effects.

Journal Articles

Abstract A94: Preventive effects of naproxen and NO‐naproxen in carcinogen induced models of urinary bladder, colon, and mammary cancers

Clinton J. Grubbs, Vernon Steele, Daniel Boring, Ronald Lubet, Chinthalapally Rao, Yuting Zhang, Jagan Patlolla

Mol Cancer Ther (2009) 8 (12_Supplement): A94.

https://doi.org/10.1158/1535-7163.TARG-09-A94

Published: 10 December 2009

View article titled, Abstract A94: Preventive effects of naproxen and NO‐naproxen in carcinogen induced models of urinary bladder, colon, and mammary cancers

Journal Articles

Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes

Ronald A. Lubet, Eva Szabo, Konstantin Christov, Ann M. Bode, Marna E. Ericson, Vernon E. Steele, M. Margaret Juliana, Clinton J. Grubbs

Mol Cancer Ther (2008) 7 (4): 972–979.

https://doi.org/10.1158/1535-7163.MCT-07-2141

Published: 15 April 2008

View article titled, Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes

Journal Articles

Preventive effects of Polyphenon E on urinary bladder and mammary cancers in rats and correlations with serum and urine levels of tea polyphenols

Ronald A. Lubet, Chung S. Yang, Mao-Jung Lee, Yukihiko Hara, Izet M. Kapetanovic, James A. Crowell, Vernon E. Steele, M. Margaret Juliana, Clinton J. Grubbs

Mol Cancer Ther (2007) 6 (7): 2022–2028.

https://doi.org/10.1158/1535-7163.MCT-07-0058

Published: 09 July 2007

View article titled, Preventive effects of Polyphenon E on urinary bladder and mammary cancers in rats and correlations with serum and urine levels of tea polyphenols

Journal Articles

Organ-specific expression profiles of rat mammary gland, liver, and lung tissues treated with targretin, 9-cis retinoic acid, and 4-hydroxyphenylretinamide

Yian Wang, Ruisheng Yao, Anna Maciag, Clinton J. Grubbs, Ronald A. Lubet, Ming You

Mol Cancer Ther (2006) 5 (4): 1060–1072.

https://doi.org/10.1158/1535-7163.MCT-05-0322

Published: 28 April 2006

View article titled, Organ-specific expression profiles of rat mammary gland, liver, and lung tissues treated with targretin, 9-cis retinoic acid, and 4-hydroxyphenylretinamide

Journal Articles

Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: prevention, therapy, and role of HaRas mutations

Ronald A. Lubet, Konstantin Christov, Ming You, Ruisheng Yao, Vernon E. Steele, David W. End, M. Margaret Juliana, Clinton J. Grubbs

Mol Cancer Ther (2006) 5 (4): 1073–1078.

https://doi.org/10.1158/1535-7163.MCT-05-0398

Published: 28 April 2006

View article titled, Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: prevention, therapy, and role of HaRas mutations

NARROW

Preclinical Evaluation of UAB30 in Pediatric Renal and Hepatic Malignancies

Preclinical Evaluation of a Novel RXR Agonist for the Treatment of Neuroblastoma

Abstract A82: Bardoxolone (5MeCDDO), which induces the antioxidant response element (ARE), is ineffective in inhibiting cancer progression but inhibits cancer initiation in rodent models of cancer. What does it mean for the ARE as a primary prevention target?

Abstract A84: Lack of efficacy of the anti-diabetic drug metformin in the ER+ methylnitrosourea (MNU)-induced and the ER⁻ MMTV-Neu/p53KO models of mammary cancer.

Abstract A80: Modified dosing schedules with the EGFr inhibitors gefitinib and lapatinib in rodent models of mammary and urinary bladder cancer: Preventive and therapeutic effects.

Abstract A94: Preventive effects of naproxen and NO‐naproxen in carcinogen induced models of urinary bladder, colon, and mammary cancers

Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes

Preventive effects of Polyphenon E on urinary bladder and mammary cancers in rats and correlations with serum and urine levels of tea polyphenols

Organ-specific expression profiles of rat mammary gland, liver, and lung tissues treated with targretin, 9-cis retinoic acid, and 4-hydroxyphenylretinamide

Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: prevention, therapy, and role of HaRas mutations

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only